Navigation Links
Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Date:12/19/2007

ymptoms of Fabry disease, including pain, kidney failure and increased risk of heart attack and stroke. Amigal is designed to selectively bind to and stabilize a-GAL, which facilitates proper trafficking of the enzyme to the lysosomes, where it is needed to break down GL-3. In a previous Phase 1 study, Amigal was shown to be safe and well tolerated and to increase GLA levels in white blood cells in healthy human volunteers. Additionally, pre-clinical studies showed that treatment of Fabry transgenic mice with Amigal can increase GLA activity and significantly reduce GL-3 accumulation in heart, kidney, skin and plasma.

Fabry disease is estimated to affect approximately 5,000 to 10,000 people in the developed world, but recent evidence suggests that the disease may be significantly under diagnosed. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan designation for Amigal in the United States, and the European Commission has designated Amigal as an orphan medicinal product in the European Union.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company has completed Phase 1 clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press rel
'/>"/>

SOURCE Amicus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... for the 13th consecutive year at the Association ... Conference and Expo. The conference brings together professionals ... technologies. This year’s event will be held from ... The three-day event draws over 1,500 healthcare technology ...
(Date:5/21/2013)... 2013 The congress of the ... is the biggest congress in Europe ... participants are in Istanbul to ... New pioneering studies have been presented: / ... ADMINISTERED VIA HEMODIALYSATE REDUCES ESA USE" By ...
(Date:5/21/2013)... NJ (PRWEB) May 21, 2013 Savoury ... industry, has appointed Dale Braddy to Southeastern USA Sales ... bolster its sales muscle in the Southeast. ... food ingredient brokerage and supplier to food processors and ... 13 years in the food industry and has over ...
(Date:5/21/2013)... May 21, 2013 Clinverse, ... company for clinical trials, announced today it has ... LLC. Clinverse’s ClinPay® FLS eClinical commerce platform ... process. SpendMD ™, Aggregate Spend Solutions’ ... for tracking and reporting transfer of value at ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3
... System will Allow Bedside Detection of Ischemic ... Events and Myocardial Infarction (Heart Attack), TEL AVIV, ... Israeli company which develops and markets systems for,non-invasive diagnosis ... detecting ischemic events using its proprietary,HyperQ technology in resting ...
... to Head Rapid Sales Growth of Leading DR and ... Image and Data Management ... Systems, a,leading developer of digital radiography (DR), PACS (Picture Archiving ... today announced it has appointed Robert Royea as,vice president of ...
... BioStorage Technologies, Inc.,(BST), announces the appointment of ... European operations in Griesheim, Germany. Hoffer,joins BST with ... fields of,clinical pharmacology and toxicology. In his new ... Chief Operating Officer for BST, and will,manage all ...
Cached Biology Technology:BSP's New Line of HyperQ Products: Bedside Ischemia Monitoring Systems Announces Successful Results of First Feasibility Study 2Royea Joins Eklin Medical Systems as VP of Worldwide Sales 2Royea Joins Eklin Medical Systems as VP of Worldwide Sales 3BioStorage Technologies Appoints Dr. Wolfgang Hoffer as Managing Director of European Operations 2
(Date:5/18/2013)... (May 18, 2013) Research presented today at Digestive ... research, with findings about the impact of coffee on ... , While coffee consumption recently has been associated with ... even a few more cups of java each month ... liver disease. Researchers at the Mayo Clinic, Rochester, MN, ...
(Date:5/17/2013)... Rutgers, The State University of New Jersey, and City ... formulation called Visikol TM that effectively clears organisms ... in place of chloral hydrate, which is one of ... is tightly regulated by the Drug Enforcement Administration (DEA) ... solutions, or clearing agents, are vital for viewing organisms ...
(Date:5/17/2013)... study finds human-caused climate change may have little ... a host of recent studies that predict their ... The findings, which appear in the journal ... survival of a creature thought to be doomed: ... cold-blooded animals, especially forest lizards, will be hard ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3Climate change may have little impact on tropical lizards 2
... streams and rivers has been significantly altered in nearly ... new nationwide USGS study. Flow alterations are a ... native species. "This USGS assessment provides the ... alteration," said Bill Werkheiser, USGS Associate Director for Water. ...
... JOLLA, CA--The Salk Institute for Biological Studies and Columbia ... grant by The Leona M. and Harry B. Helmsley ... use of induced pluripotent stem (iPS) cells to gain ... therapeutic drugs. "Stem cell research is of immense ...
... built-in timer intended to improve the accuracy of paper ... and elsewhere. Their study appears in ACS, semi-monthly journal ... Hyeran Noh note that so-called point-of-care tests include paper ... instead of in laboratories. They show special promise for ...
Cached Biology News:Most river flows across the US are altered by land and water management 2Helmsley Charitable Trust awards more than $15 million to Salk Institute-CUMC 2Helmsley Charitable Trust awards more than $15 million to Salk Institute-CUMC 3Built-in timer for improving accuracy of cost saving paper-strip medical tests 2